Moderna has announced that its COVID-19 vaccine was 93% effective, with “durable” efficacy lasting at least 6 months after administration of the second dose.
The company also said that it tested three booster candidates, which showed “robust antibody responses to COVID-19 variants of concern.”
The data on the Moderna vaccine’s durability are from a final analysis of the phase 3 COVE study, according to a press release. The company said it has begun the rolling submission process for a Biologics License Application for its COVID-19 vaccine, and it anticipates